Virology
TWiV 949: Clinical update with Dr. Daniel Griffin
By Vincent Racaniello
In his weekly clinical update Dr. Griffin discusses progress toward poliomyelitis eradication in Pakistan, polio by the numbers , influenza and COVID-19 vaccination coverage among health care personnel, phase 1/2a safety and immunogenicity of an adenovirus 26 vector RSV vaccine encoding prefusion F in adults 18–50 years and RSV seropositive ...
TWiV 948: Breathless with David Quammen
By Vincent Racaniello
David Quammen returns to TWiV to discuss how he wrote his new book 'Breathless', a story about the science and the scientists behind the race to understand the pandemic coronavirus SARS-CoV-2. Hosts: Vincent Racaniello, Rich Condit, Kathy Spindler, and Brianne Barker Guest: David Quammen Click arrow to playDownload TWiV 948 (68 MB ...
TWiV 947: Clinical update with Dr. Daniel Griffin
By Vincent Racaniello
In his weekly clinical update Dr. Griffin discusses the prediction of upcoming global infection burden of influenza seasons after relaxation of public health and social measures during the COVID-19 pandemic, severe COVID-19 outcomes after full vaccination of primary schedule and initial boosters, and how successful immunomodulators for treatment of COVID-19 have opened ...
TWiV 946: Poo vs flu
By Vincent Racaniello
Angela Mingarelli joins TWiV to discuss whether the gut microbiota of bats confers tolerance to influenza virus infection in mice, and primate hemorrhagic fever-causing arteriviruses that can reproduce in human cells and might be capable of infecting humans. Hosts: Vincent Racaniello, Dickson Despommier, Alan Dove, Rich Condit, and Brianne Barker Guest: ...
TWiV 945: Clinical update with Dr. Daniel Griffin
By Vincent Racaniello
In his weekly clinical update Dr. Griffin discusses a healthcare-associated infection with Monkeypox virus, air and surface sampling for monkeypox virus in a UK hospital, misrepresentation and nonadherence regarding COVID19 public health measures, tolerability and immunogenicity of an intranasally-administered adenovirus-vectored COVID-19 vaccine, clinical, virologic, and immunologic evaluation of symptomatic rebound following Nirmatrelvir/Ritonavir treatment, early outpatient treatment ...
